Page 373 of 1,034: studies 3,721 to 3,730 of 10,336, newest first. Back to the depression overview
JMIR Formative Research March 4, 2024 Grant Jones, Felipe Herrmann, Adam Bear et al. 2 citations
This study demonstrates that changes in mindfulness predict subsequent changes in well-being in a data set including individuals who recently engaged in psychedelic use.
JMIR mHealth and uHealth March 4, 2024 Christine E Callahan, Justin Kimber, Emily A. Hu et al. 18 citations
Perceived stress in the United States has drastically increased since the COVID-19 pandemic and is associated with negative mental health outcomes such as depression and anxiety. Digital mental health (DMH) interventions are efficacious tools to address negative mental health outcomes and have helped reduce the severity of psychological symptoms, such as anxiety, depression, and perceived...
Journal of Pharmacological Sciences March 1, 2024 Aimi Yamagishi, Yuiko Ikekubo, Masayoshi Mishina et al. 6 citations
Ketamine, an N-methyl-d-aspartate (NMDA) receptor antagonist, has attracted attention for its acute and sustained antidepressant effects in patients with depression. Hydroxynorketamine (HNK), a metabolite of ketamine, exerts antidepressant effects without exerting ketamine's side effects and has attracted much attention in recent years. However, the detailed pharmacological mechanism of action...
Psychedelic Medicine March 1, 2024 Justin C Strickland, Albert Garcia‐romeu, Matthew W Johnson 20 citations
The Mystical Experience Questionnaire (MEQ-30) and Challenging Effects Questionnaire (CEQ) are two of the most widely used, validated instruments to probe subjective effects of psychedelic drugs. However, these assessments are lengthy and can be a burden to study participants or patients if administered during acute psychedelic effects, after resolution of psychedelic effects when participants...
Psychedelic Medicine March 1, 2024 Meghan Hibicke, Gerald Billac, Charles D. Nichols 2 citations
Psychedelics such as psilocybin have been shown to have persistent antidepressant effects, but with considerable individual variability in optimal dosing. Intravenous (IV) dosing is rapid onset and quickly titrated, possibly preceded by an anxiolytic for patient comfort. We explored the viability of IV psilocin with and without preadministration of lorazepam for possible future inpatient...
Molecules February 22, 2024 Hanbo Yao, Xiaodong Wang, Jiaxin Chi et al. 9 citations
Major Depressive Disorder (MDD) is a complex mental disorder that involves alterations in signal transmission across multiple scales and structural abnormalities. The development of effective antidepressants (ADs) has been hindered by the dominance of monoamine hypothesis, resulting in slow progress. Traditional ADs have undesirable traits like delayed onset of action, limited efficacy, and...
Journal of Medical Internet Research February 20, 2024 Huijing Zou, Sek Ying Chair, Bilong Feng et al. 15 citations
Psychological distress is common among patients with acute coronary syndrome (ACS) and has considerable adverse impacts on disease progression and health outcomes. Mindfulness-based intervention is a promising complementary approach to address patients' psychological needs and promote holistic well-being. This study aims to examine the effects of a social media-based mindfulness...
BMC cardiovascular disorders February 14, 2024 Qiongshan Chen, Hui Liu, Shizheng Du 23 citations
Hypertension and prehypertension have been widely recognized as the main contributors of global mortality. Evidence shows mindfulness-based interventions may reduce blood pressure and improve mental health. However, the effect of mindfulness-based interventions on blood pressure and mental health has not been fully understood. Potential studies published before May 24th 2023 were identified by...
Journal of Ethnopharmacology February 10, 2024 Alberto Hernández-león, Raúl Iván Escamilla-Orozco, Aylín R. Tabal-Robles et al. 29 citations
Central nervous system (CNS) diseases can be diverse and usually present with comorbidity, as in the case of depression and anxiety. Despite alternatives like Psilocybe mushrooms for mental health there is no basic research to evidence their CNS benefits. To evaluate the anxiolytic- and antidepressant-like effects, as well as the acute toxicity of P. cubensis mushroom. First, the acute toxicity...
Frontiers in Neuroscience February 7, 2024 Jennifer Warner-Schmidt, Martin Stogniew, Blake Mandell et al. 6 citations
BackgroundPost-traumatic stress disorder (PTSD) is a highly prevalent psychiatric disorder that can become chronic and debilitating when left untreated. Available pharmacotherapies are limited, take weeks to show modest benefit and remain ineffective for up to 40% of patients. Methylone is currently in clinical development for the treatment of PTSD. Preclinical studies show rapid, robust and...